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Abstract
Background: Cystic fibrosis (CF) is a multisystem disorder characterised by mutations of the
CFTR  gene, which encodes for an important component in the coordination of electrolyte
movement across of epithelial cell membranes. Symptoms are pulmonary disease, pancreatic
exocrine insufficiency, male infertility and elevated sweat concentrations. The CFTR gene has
numerous mutations (>1000) and functionally important polymorphisms (>200). Early identification
is important to provide appropriate therapeutic interventions, prognostic and genetic counselling
and to ensure access to specialised medical services. However, molecular diagnosis by direct
mutation screening has proved difficult in certain ethnic groups due to allelic heterogeneity and
variable frequency of causative mutations.
Methods: We applied a gene scanning approach using DHPLC system for analysing specifically all
CFTR exons and characterise sequence variations in a subgroup of CF Italian patients from the Lazio
region (Central Italy) characterised by an extensive allelic heterogeneity.
Results:  We have identified a total of 36 different mutations representing 88% of the CF
chromosomes. Among these are two novel CFTR mutations, including one missense (H199R) and
one microdeletion (4167delCTAAGCC).
Conclusion: Using this approach, we were able to increase our standard power rate of mutation
detection of about 11% (77% vs. 88%).
Background
Cystic fibrosis (OMIM #219700) is one of the most com-
mon genetic diseases in Caucasians with a frequency of 1/
3500 [1,2]. Affected children have two mutations in the
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CFTR gene (CFTR/ABCC7, OMIM #602421), a gene that
contains 27 exons encompassing approximately 180 kb of
DNA on chromosome 7q31.2. CFTR protein is a Cl- chan-
nel, which regulates ion flow across the apical membrane
of airway, gastrointestinal and reproductive epithelia, and
of sweat glands and pancreatic ducts [3-6]. Over 1000
mutations have been described in the Cystic Fibrosis
Mutation Consortium [7], mutations that are clustered in
six different classes including defective CFTR biosynthesis,
defective protein processing, alteration in CFTR regula-
tion, disruption of the pore activity, alteration of CFTR
localisation, and genesis of unstable CFTR [8]. The most
common mutation is a deletion of three nucleotides
(1652delCTT) that leads to a loss of a phenylalanine resi-
due at position 508 (delF508) of the gene product. This is
responsible for approximately two thirds of all CF chro-
mosomes, with a clear Northwest to Southeast gradient in
its frequency in the human population across Europe [9].
There is a core of 25 "less common" mutations designated
by the CF Steering Committee in 2001 that occur with a
European frequency of 0.1% or greater. The remainder of
the mutations are termed "rare", being found in only one
or few individuals [9]. The spectrum of CFTR-associated
phenotypes is quite variable, going from classic CF to mild
monosymptomatic presentations, like idiopathic pancre-
atitis, chronic rhinosinusitis, nasal polyposis, asthma, dis-
seminated bronchiectasis and congenital bilateral absence
of the vas deferens (CBAVD) [10]. Some mutations are
clearly associated with a mild phenotype (with pancreatic
insufficiency and a life expectancy over 50 years) [8].
Other attempts to link mutations in CFTR to disease sever-
ity have not been successful, suggesting an influence of
non-CFTR gene modifiers and environmental factors [11].
CF diagnosis is based on defined phenotypic criteria, on
CF history in the family and/or a positive test for hyper-
trypsinaemia (IRT) in the neonatal period. In the majority
of cases, the diagnosis of CF is confirmed by elevated (>60
nmol/l) sweat chloride concentrations, and by a raised
electrical potential difference (NPD) across the nasal epi-
thelium. Molecular diagnosis is based on CFTR mutation
screening. However, extensive allelic heterogeneity fre-
quently impairs the rate of detection and therefore the
value of the genotypic diagnosis. Several mutation scan-
ning methods have been applied to the detection of
sequence variations in the entire coding region of CFTR
such as heteroduplex analysis and restriction enzyme
analysis [12], single-strand conformation polymorphism
analysis (SSCP) [13], and the DGGE method [14,15].
Recently, two different groups have used the DHPLC tech-
nology to detect CF alleles [16-18]. We analysed a cohort
of CF patients clinically defined from Central Italy (an
area characterized by an high allelic heterogeneity) [9] for
the presence of CFTR mutations by using this technique to
optimize mutation detection. The results presented here
not only provide a comprehensive spectrum of the molec-
ular basis of CF in the Central Italy, but also underscore
the need for multi-approach screening of CFTR gene in




All CF patients came from the population of children
born in Central Italy (diagnosis performed using standard
clinical criteria at Ospedale Bambino Gesù, Roma). Sam-
ples were included for DHPLC screening on the basis of
presentation of family history and/or abnormal sweat
tests. All 290 samples were analysed for the 29 common
mutations by INNO-LiPA CFTR12 and CFTR17+Tn assays
(Innogenetics NV, Zwijndrecht, Belgium) as part of the
routine testing service provided at the centre. During the
course of the study, 117 samples were shown to have only
one or none of the 29 common mutations tested and were
selected for further investigation. DNA from healthy sub-
jects was randomly chosen as controls. Their DNA was
sequenced and the entire CFTR gene sequence was con-
firmed to be wild-type with respect to CFTR. Genomic
DNA was isolated from peripheral blood leukocytes using
a salting-out protocol.
DNA amplification
Coding regions and intron/exon boundaries of the CFTR
gene were amplified in 29 reactions using primers
described by Le Marechal et al. [17]. A novel primer design
was only required for exons 6b and 9 to improve the PCR
sensitivity. Fifty to 100 ng of genomic DNA from different
patients were used for the PCR reaction. Amplification
was performed in a 25 µl reaction volume containing 0.2
mM each of primers, 200 µM dNTPs, 1X reaction buffer
(10 mM Tris HCl pH 8.3, 50 mM KCl, 2.5 mM MgCl2) and
1.25 U AmpliTaq Gold™ DNA polymerase (PE Applied
Biosystems, Foster City, CA) by a Gene Amp PCR System
9700 (PE Applied Biosystems, Foster City, CA). PCR
amplification was carried out at 94°C for 10 min and then
cycled 35 times at 94°C for 40 sec, 57°C or 61°C for 40
sec and 72°C for 1 min, followed by 7 min at 72°C in the
final cycle. Amplicons were checked by agarose gel elec-
trophoresis before DHPLC analysis, to make sure that
only the specific product was amplified.
DHPLC analysis
DHPLC analysis was carried out on a WAVE DNA frag-
ment analysis system (Transgenomic™, Crewe, UK)
equipped with a DNASep®  Column (Transgenomic™,
Crewe, UK). PCR products was denatured for 5 min at
95°C before being gradually reannealed by decreasing
sample temperature from 95 to 65°C over a period of 30
min to enable the formation of heteroduplexes. DHPLC
analysis was carried out at a flow-rate of 0.9 ml/min andBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/8
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buffer B (0.1 M TEAA, 25% acetonitrile), with a gradient
increase of 2% per min for 4 min. The start and end con-
centration of buffer B and oven temperature for optimal
heteroduplex separation have previously been described
[17].
Data analysis
Four wild-type samples were always used as negative con-
trols, to ensure that a normal homoduplex profile was
reproducibly obtained with regard to retention time and
peak profile. Chromatograms were overlaid with one
from a wild-type. Samples with extra peaks (one, two or
three more), or with a difference in peak appearance, were
scored as positive.
Sequence analysis
Samples showing abnormal elution profile were reampli-
fied from genomic DNA. PCR products were purified with
GeneDia Seq-Prep Kit and were sequenced in both direc-
tions using CEQ™ 2000 (Beckman Coulter Inc. USA).
Results
CF patients were firstly screened using a standard panel of
29 different CF mutations (INNO-LiPA CFTR12 and
CFTR17+Tn). Of these, 173 were homozygous or com-
pound heterozygous (+/+), 105 were positives for only
one mutations (+/-) and 12 were negative for both muta-
tions (-/-). The unknown alleles were screened by DHPLC
technology. In order to set-up elution conditions and pro-
files of known mutations not included in the INNO-LiPA
kits, we ran amplicons obtained from DNAs carrying 10
rare CFTR mutations previously found and identified by
sequencing in compound heterozygote CF patients from
an area of Central Italy [19]. These mutations included
S4X (143 C to A), exon 1; S42F (257 C to T), exon 2;
R117L (482 G to T), exon 4; S549R (1779 T to G), exon
11; 3667ins4, exon 19; A1006E (3149 C to A), exon17a;
L1065P (3326 T to C), R1066C (3328 C to T), L1077P
(3362 T to C), exon 17b. DHPLC profiles are shown in
Figure 1. In contrast to the normal control that shows a
single peak of homoduplex DNA, all samples with previ-
ously identified mutations produced chromatograms of a
different shape. New primers were synthesised only for
exons 6b and 9, and they annealed to the coding sequence
(Table 1). DHPLC conditions were set up according to
WAVEmaker software (Transgenomic) and the DHPLC
Melt program (Table 1) [20]. The complete spectrum of
mutations detected in the sample is reported in Table 2. A
total of 36 different mutations, including 22 missense, 4
nonsense, 6 micro insertion/deletion and 4 splicing muta-
tions were detected. Only six mutations have a frequency
>1%, which account for 77.5 % of the total CF chromo-
somes. Nineteen mutations have frequencies between
0.9% and 0.4%, and cover 8.36% of the CF chromo-
somes. Finally, 11 mutations were found only once in the
population, increasing the proportion of the characterised
CF alleles by 1.87% (data not shown). Among these muta-
tions, we have identified and characterised in the Italian
population two novel mutations in two affected children:
H199R and 4167delCTAAGCC. An abnormal DHPLC
pattern in exon 6a due to the nucleotide change A to G at
position 728 of CFTR determines the missense mutation
H199R that falls into the transmembrane domain, TM1.
This CF mutation was identified in a patient who carries
the N1303K (4041 C to G) mutation on the maternal CF
chromosome. H199R mutation, to our knowledge, has
been detected in a single CF chromosome in a population
in Brittany [7]. The other two mutations that affect the
same codon are described: H199Y (727 C to T), found in
a German CF patient heterozygous for delF508 and who
exhibits only mild pancreatic symptoms and borderline
sweat chloride values, and H199Q (729 T to G). The
microdeletion 4167delCTAAGCC in exon 22 was identi-
fied by DHPLC analysis in a CF patient who presents the
L1065P (3326 T to C) mutation on the maternal chromo-
some. This mutation leads to a premature stop codon,
resulting in the deletion of 90 carboxyterminal amino
acid residues. Consequently, the NBF2 intracellular
domain, which constitutes a CFTR ATP binding domain,
is lost. These two novel mutations were not found in a
group of 100 healthy controls. Furthermore, in both cases,
no other alterations were observed after the complete
screening of all the coding and flanking regions of CFTR
gene. DHPLC analysis also revealed 8 DNA sequence var-
iations (Table 3). In some cases these variations co-segre-
gated with pathogenic CF mutations within the same
fragment, resulting in an altered DHPLC profile. Finally,
in a single CF patient, we detected two different mutations
[G542X (1756 G to T) and S549R (1779 T to G)] in the
same exon 11-derived DNA amplicon, which showed a
peculiar DHPLC pattern, different from that observed
when only one of these mutations was present (data not
show).
Overall, these results revealed a detection rate of 88%,
increasing the standard level of detection by ~11%.
Discussion
Prior to complete gene analysis ~77% of the mutant alle-
les could be detected by screening with various commer-
cially available mutation panels. CFTR gene analysis by
DHPLC presented here allowed identification of an addi-
tional 11% of mutant alleles, including nine rare muta-
tions and 2 novel ones, underlying the high mutational
heterogeneity for CF in this Italian population. The two
novel mutations identified could be pathogenic because
they determine significant alterations in the protein.
H199R has a substitution of a conserved amino acid cru-
cial in the TM1 domain, while the other, a 7bp-deletion,BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/8
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introduces a premature STOP codon, resulting in a trun-
cated protein.
Mutation screening of newborns clinically suspected of
having cystic fibrosis can contribute to the confirmation
of diagnosis, and in some instances may help to predict
the severity of the disease. This can lead to early treatment
to retard irreversible tissue damage and ensure the highest
possible quality of life for these individuals. The level of
detection is therefore important, and this will depend on
the sensitivity of the method used. Routine methods, i.e.
INNO-LiPA  CFTR  assay, include a bias since they are
based on a selection of known mutations, established on
the basis of mutations frequently occurring in North Cau-
casians. Due to the large number of mutations found in
the CFTR gene and their variable frequency among differ-
DHPLC chromatograms corresponding to nine different CFTR mutations from heterozygous patients compared to a normal  sample (WT) Figure 1
DHPLC chromatograms corresponding to nine different CFTR mutations from heterozygous patients compared to a normal 
sample (WT). The profiles of the mutants show extra peaks or a shoulder and are easily distinguished from profiles of the wild 
type, which shows a single peak.
Table 1: Primers and DHPLC (oven temperature, gradient) analysis conditions for 6b and 9 exons of the CFTR gene
exon Primer 5' → 3' Amplicon length Oven temp (°C) % B buffer start/end
6b F – CAGAGATCAGAGAGCTGGG 323 56 55/63
R – GAGGTGGAAGTCTACCATGA
9 F – GGGATTTGGGGAATTATTTG 279 55 54/62
R – TCTCCAAAAATACCTTCCAGBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/8
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Table 2: CF mutations identified in cohort of 290 patients from the Central Italy
Mutation Nucleotide change Exon/intron N % Method
delF508 1652delCTT 10 328 56.36 INNO-LiPA, DHPLC
N1303K 4041 C to G 21 51 8.76 INNO-LiPA, DHPLC
G542X 1756 G to T 11 42 7.21 INNO-LiPA, DHPLC
W1282X 3978 G to A 20 15 2.60 INNO-LiPA, DHPLC
S549R 1779 T to G 11 8 1.37 DHPLC
621+1G-T 621+1 G to T Intron 4 7 1.20 INNO-LiPA, DHPLC
1717-1G-A 1717-1 G to A Intron 10 5 0.86 INNO-LiPA, DHPLC
G85E 386 G to A 3 4 0.69 INNO-LiPA, DHPLC
R553X 1789 C to T 11 4 0.69 INNO-LiPA, DHPLC
H139R 548 A to G 6a 3 0.51 DHPLC
R347P 1172 G to C 7 3 0.51 INNO-LiPA, DHPLC
L1065P 3326 T to C 17b 3 0.51 DHPLC
L1077P 3362 T to C 17b 3 0.51 DHPLC
S4X 143 C to A 1 2 0.34 DHPLC
D110H 460 G to C 4 2 0.34 DHPLC
R334W 1132 C to T 7 2 0.34 INNO-LiPA, DHPLC
M348K 1175 T to A 7 2 0.34 DHPLC
1259insA 1259 ins A 8 2 0.34 DHPLC
S549N 1778 G to A 11 2 0.34 DHPLC
L558S 1805 T to C 11 2 0.34 DHPLC
2183+AA-G 2183 A to G and 2184 del A 13 2 0.34 INNO-LiPA, DHPLC
2789+5G-A 2789+5 G to A Intron 14b 2 0.34 INNO-LiPA, DHPLC
R1066C 3328 C to T 17b 2 0.34 DHPLC
3667ins4 3667insTCAA 19 2 0.34 DHPLC
S42F 257 C to T 2 2 0.34 DHPLC
R117L 482 G to T 4 1 0.17 DHPLC
H199R 728 A to G 6a 1 0.17 DHPLC
R334L 1133 G to T 7 1 0.17 DHPLC
T338I 1145 C to T 7 1 0.17 DHPLC
G551D 1784 G to A 11 1 0.17 INNO-LiPA, DHPLC
Q552X 1786 C to T 11 1 0.17 INNO-LiPA, DHPLC
D614G 1973 A to G 13 1 0.17 DHPLC
A1006E 3149 C to A 17a 1 0.17 DHPLC
4016insT 4016 ins T 21 1 0.17 DHPLC
4040delA 4040 del A 21 1 0.17 DHPLC




N = number of CF chromosomes; % = frequency.
Table 3: Polymorphisms (*) identified in our cohort of CF patients by DHPLC
Polymorphism Nucleotide change Exon/intron
125G/C 125 G to C 5' UTR
R75Q 356 G to A 3
875+40A/G 875+40A/G Intron 6a
M470V 1540 A to G 10
T854T 2694 T to G 14a
T966T 3030 G to A 15
4006-199G/A 4006-199G/A Intron 20
P1306P 4050 C to T 21
(*) According to [7].BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/8
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ent ethnic and racial groups, it is difficult to develop a
suitable assay for all populations that covers all known
mutations. With the exception of a few genetically homo-
geneous populations (i.e. Ashkenazi Jewish, Brittany and
Quebec populations), the detection rate of CFTR muta-
tions in heterogeneous populations varies between 88
and 90% [17,21-27]. Our experience is that the DHPLC
technique is useful in mutation detection in heterogene-
ous ethnic populations in Central and South Italy. In
these populations, we have now reached a detection sen-
sitivity similar to that observed in other Italian regions
and other Mediterranean populations, where a relatively
low frequency of delF508 mutation is detected.
Conclusions
In this study, we scanned the entire exonic region of the
CFTR gene in genomic DNA obtained from a cohort of
290 CF patients. We were able to identify two pathogenic
mutations by DHPLC technique in 211 subjects. In the
remaining cases, at least a single CF allele was detected.
The pattern of the elution profile for heteroduplex analy-
sis has shown that this technique has proved to be able to
distinguish the disease-causing mutations of the CFTR
gene. However, in our experimental conditions, some-
times we found difficult to correlate the profile of DHPLC
chromatograms with the mutation type. Consequently,
further confirmation of the sequence variants by direct
sequencing is necessary. Overall, DHPLC has been shown
to be a reliable, sensitive, and specific screening method
to rapidly detect CFTR mutations, that account for about
88% of CF alleles in our population. In addition, this
semi-automated method would also be quite suitable for
rapid mutational screening of unknown mutations.
These data also illustrate the need for a multi-system scan-
ning approach. In fact, although the sensitivity was ele-
vated, a significant rate of failure in 69 alleles analysed out
of 580 (11.90%) was observed. The extension of DHPLC
analysis to the non-coding regions, including promoter
and regulatory regions, further increases the detection
rate. However, our opinion is that even extensive DHPLC
analysis of the whole CFTR gene would not increase the
detection rate above 95% in our population. This is
because larger genomic rearrangements occurring in some
CF cases, and/or technical reasons (i.e. DNA quality,
primers design, fragment length), can affect DHPLC.
To maximize mutation detection, different techniques
need to be employed, including DHPLC, Southern analy-
sis, and expression studies. Recently, it has been demon-
strated that the screening of large deletions by quantitative
multiplex polymerase chain reaction of short fluorescent
fragment (QMPSF) can improve the detection of unchar-
acterised CF alleles [28]. Therefore, on this basis, we rec-
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